HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
Not recruitingEUCTR 2006-006967-22

A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects with Schizophrenia

This historical record does not confirm current site availability.

Historical research recordMultiple countries
The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who could participate?

This study is for people with schizophrenia. Other eligibility criteria apply.

Listed locations
Estonia · France and 8 more locations
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Not recruiting
Enrollment listed in the registry
456
Sponsor
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
France, United Kingdom, Estonia, ...
Age range
Not clearly listed
Official registry ID
EUCTR 2006-006967-22
Official title
Show the full official title

A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects with Schizophrenia

Questions about this study?

The HopeStage team will email you.

Loading the security check...

Recruitment & locations

Not recruiting

Estonia · France · Greece

7 more locations
  • Italy
  • Latvia
  • Lithuania
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
Checked Official study record (opens in a new tab)
Registry details
Historical country statuses

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Who can participate?

This study is for people with schizophrenia. Other eligibility criteria apply.

Is this study still recruiting?

The historical registry lists this study as not recruiting.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me